[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"upper-aerodigestivetract-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:upper-aerodigestivetract-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100639254","ai-assisted-endoscopy-for-upper-aerodigestive-tract-lesions-100639254",false,"NCT07596355","AI-Assisted Endoscopy for Upper Aerodigestive Tract Lesions","Head&Neck Application of Novel Computer-assisted Endoscopy","H&NANCE","Inclusion Criteria:\n\n* Age \\> 18 years\n* Injury originating from the upper aero-digestive tract\n* Recording of the video-endoscopic examination\n* Patient known to undergo a biopsy of the lesion or clinical follow-up for lesion with known biopsy (e.g. laryngeal papillomatosis) or suffering from Reinke's edema (in this pathology, in fact, biopsy is not necessary since the diagnosis is clinical)\n* Or patients undergoing transoral lesion excision\n\nExclusion Criteria:\n\n* Submucosal lesion\n* Patients with previous operations on the upper aero-digestive tract\n* Patients with previous radiotherapy of the head and neck district\n* Poor compliance on endoscopic examination\n* Unavailability of CADe\u002FCADx or CASe data logging note","ALL","18 Years",{"count":20,"type":21},283,"ESTIMATED","OBSERVATIONAL","This is a prospective observational clinical study designed to evaluate the performance of artificial intelligence (AI) algorithms applied to upper aerodigestive tract (UADT) video-endoscopy. The study assesses three main tasks: lesion detection (localization), classification (benign vs malignant), and segmentation of tumor margins.\n\nAI algorithms will be applied to endoscopic video data acquired during routine clinical practice without influencing clinical decision-making. The system will process images in real time and store data for subsequent analysis. AI outputs will be compared with physician assessment and reference standard histopathology to evaluate diagnostic performance.",[25,26,27,28,29,30,31,32,33],"Upper Aerodigestive Tract Neoplasms","Upper AerodigestiveTract Cancer","Upper Aero-digestive Tract (UADT) Neoplasm","Squamous Cell Carcinoma","Leukoplakia","Head and Neck Cancer (H&N)","Vocal Cord Disease","Vocal Fold Polyp","Vocal Fold Nodules","NOT_YET_RECRUITING","2026-05-12",{"date":37,"type":38},"2026-05-19","ACTUAL",{"date":40,"type":21},"2026-05",{"date":42,"type":21},"2028-02",{"name":44,"class":45},"Istituto Italiano di Tecnologia","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100621935","metabolomics-of-cancers-of-the-upper-aerodigestive-tract-100621935","NCT07377084","Metabolomics of Cancers of the Upper Aerodigestive Tract","METABORL","Inclusion Criteria:\n\n* Histologically proven squamous cell carcinoma of the upper aerodigestive tract (oral cavity, oropharynx, larynx, and hypopharynx), stage T1-4, N0-3, M0, untreated.\n* Curative treatment planned at CAL.\n* Patient who has voluntarily consented to the use of their data and signed a non-opposition form for the use of their biological and tumor samples.\n\nExclusion Criteria:\n\n* Metastatic patient (M1).\n* No curative treatment possible.\n* History of cancer (other than basal cell carcinoma) in the last 5 years.\n* Tumor size deemed insufficient according to the assessment of the ENT surgeon.\n* Patient refusal to allow the use of their biological and tumor samples for research.\n* Vulnerable persons are defined in articles L1121-5 to -8:\n\n  * Pregnant women, women in labor, and nursing mothers, individuals deprived of liberty by a judicial or administrative decision, individuals hospitalized without consent under articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of article L. 1121-8,\n  * And individuals admitted to a health or social establishment for purposes other than research,\n  * Adults under legal protection or unable to express their non-opposition.",{"count":55,"type":21},250,"Metabolomics, thanks to advances in mass spectrometry, allows for the analysis of cellular metabolites to better understand biological processes. In oncology, it provides a global view of metabolic alterations in tumors and enables the classification of cancers based on various medical parameters using advanced statistical methods (machine learning). Its low cost and speed make it a promising approach in personalized medicine.\n\nCancers of the upper aerodigestive tract (UADT), the fifth most common cancer in France, are often diagnosed late, reducing survival chances (35-50% at five years). Identifying a specific metabolomic signature for these cancers could facilitate early detection, assess treatment response, and rapidly detect recurrences. Additionally, HPV-induced tumors may exhibit a distinct metabolic profile compared to those caused by tobacco and alcohol. Currently, no published studies have explored this topic for UADT cancers, highlighting the need for such research.\n\nThe aim of this study is to identify a metabolomic signature associated with the presence of UADT cancer at initial diagnosis and during post-therapeutic follow-up (three months after treatment completion). Hypothesis is that a specific metabolomic signature will be observed in the biological samples of patients diagnosed with UADT cancer, that the type of observed signature could be correlated with tumor site, stage, HPV status, and prognosis, and that the persistence or disappearance of this metabolomic signature three months after treatment may be associated with the risk of recurrence. The search for this potential metabolomic signature will be conducted using tumor biopsies, plasma, and urine samples at the initial diagnostic phase and plasma and urine samples at three and six months post-treatment follow-up.\n\nUltimately, the benefits of this study lie in improving early diagnosis, treatment (adjusting treatment based on the prognostic value of specific metabolomic signatures), and follow-up (early detection of recurrences, adapting monitoring to each patient's individual risk) of UADT cancers.\n\nAs the study is based on biological samples collected as part of standard patient care (with no additional biological tests or procedures performed specifically for research), no research-related risk is expected for the patient.\n\nThis is a prospective, single-center study involving patients with histologically confirmed, untreated squamous cell carcinoma of the UADT (oral cavity, oropharynx, larynx, and hypopharynx) who will receive curative treatment at the Antoine Lacassagne Center.\n\nThe search for a potential metabolomic signature will be conducted using biological and tumor samples collected as part of standard patient care, without requiring additional tests or procedures.\n\nThe primary objective of the study is to identify a metabolomic signature in patients with UADT cancer.\n\nThe secondary objectives of the study are:\n\n* To investigate the correlation between a metabolomic signature and tumor characteristics.\n* To examine the relationship between a metabolomic signature at three to six months post-treatment and oncological status at three to six months and one year post-treatment in patients with UADT cancer.",[26],"RECRUITING","2026-01-22",{"date":61,"type":38},"2026-01-29",{"date":63,"type":38},"2020-11-04",{"date":65,"type":21},"2027-05",{"name":67,"class":45},"Centre Antoine Lacassagne",1]